NCT05058560View on ClinicalTrials.gov

Tislelizumab in Addition to BACE in Patients with NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

February 4, 2025

Study Completion Date

February 15, 2025

Conditions
NSCLC
Interventions
DRUG

Tislelizumab

tislelizumab, 200 mg IV Q3W, up to one year.

Trial Locations (1)

450000

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Zhengzhou University

OTHER

NCT05058560 - Tislelizumab in Addition to BACE in Patients with NSCLC | Biotech Hunter | Biotech Hunter